基于TCGA数据库肝细胞癌microRNA-324-5p表达与预后危险因素分析

doi:10.16139/j.1007-9610.2021.03.015

摘要/Abstract

摘要：

目的：探究microRNA-324-5p（miR-324-5p）在肝细胞癌（hepatocellular carcinoma, HCC）组织中的表达与病人预后危险因素。方法：通过TCGA（The Cancer Genome Atlas）数据库获得的肿瘤组织和正常肝组织miRNA表达谱数据与病人临床信息,分析miR-324-5p表达差异与病理的关系。通过绘制生存曲线分析miR-324-5p表达与病人预后的相关性。单因素和多因素Cox回归模型分析HCC相关危险因素。结果：miR-324-5p在HCC表达高于正常组织（P<0.001）,且与不良预后相关。多因素Cox分析表明miR-324-5p可作为HCC预后不良的独立危险因素（P<0.05）。结论：miR-324-5p在HCC组织过表达,是HCC病人总生存期缩短的独立危险因素,为HCC预后判断的潜在生物学标志物。

关键词: 肝细胞癌, microRNA-324-5p, 生物学标志物

Abstract:

Objective To study the expression of microRNA-324-5p (miR-324-5p) in hepatocellular carcinoma (HCC) and the prognosis risk factor in patients with HCC. Methods MiRNA expression database in tissue of both tumor and normal liver combined with clinical data of HCC patients were collected from The Cancer Genome Atlas (TCGA) database. Relationship between miR-324-5p expression and pathological features was analyzed. Relation of miR-324-5p expression to prognosis of the patients was analyzed through survival curve. Univariate and multivariate Cox regression models were used to analyze the risk factors related to HCC. Results The expressions of miR-324-5p in HCC were higher than those in normal tissues(P<0.001) and were associated with poor prognosis. Multivariate Cox analysis showed that miR-324-5p was an independent risk factor for HCC (P<0.05). Conclusions MiR-324-5p is upregulated in HCC, which play a role as risk factor in the HCC patients with shorten suvival and may be a possible biomarker of HCC prognosis prediction.

Key words: Hepatocellular carcinoma, MicroRNA-324-5p, Biomarker

中图分类号:

R735.7

吴城孝, 方婕, 周霁川, 肖永胜, 张晓光. 基于TCGA数据库肝细胞癌microRNA-324-5p表达与预后危险因素分析[J]. 外科理论与实践, 2021, 26(03): 249-253.

WU Chengxiao, FANG Jie, ZHOU Jichuan, XIAO Yongsheng, ZHANG Xiaoguang. Expression of microRNA-324-5p in hepatocellular carcinoma based on the Cancer Genome Atlas (TCGA) database and analysis of prognosis risk factor[J]. Journal of Surgery Concepts & Practice, 2021, 26(03): 249-253.

图/表 4

表1

图1

图2

表2

参考文献 19

[1]	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28.
[2]	Dai M, Chen S, Wei X, et al. Diagnosis, prognosis and bioinformatics analysis of lncRNAs in hepatocellular carcinoma[J]. Oncotarget, 2017, 8(56):95799-95809. doi: 10.18632/oncotarget.21329 URL
[3]	Jiang Y, Sun A, Zhao Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma[J]. Nature, 2019, 567(7747):257-261. doi: 10.1038/s41586-019-0987-8 URL
[4]	Liu YR, Tang RX, Huang WT, et al. Long noncoding RNAs in hepatocellular carcinoma: novel insights into their mechanism[J]. World J Hepatol, 2015, 7(28):2781-2791. doi: 10.4254/wjh.v7.i28.2781 URL
[5]	Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers[J]. Nature, 2005, 435(7043):834-838. doi: 10.1038/nature03702 URL
[6]	Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer[J]. J Pathol, 2011, 223(2):102-115. doi: 10.1002/path.2806 URL
[7]	Gu C, Zhang M, Sun W, et al. Upregulation of miR-324-5p inhibits proliferation and invasion of colorectal cancer cells by targeting ELAVL1[J]. Oncol Res, 2019, 27(5):515-524. doi: 10.3727/096504018X15166183598572 URL
[8]	Wan Y, Luo H, Yang M, et al. miR-324-5p contributes to cell proliferation and apoptosis in pancreatic cancer by targeting KLF3[J]. Mol Ther Oncolytics, 2020, 18:432-442. doi: 10.1016/j.omto.2020.07.011 URL
[9]	Xu HS, Zong HL, Shang M, et al. MiR-324-5p inhibits proliferation of glioma by target regulation of GLI1[J]. Eur Rev Med Pharmacol Sci, 2014, 18(6):828-832.
[10]	Ishak K, Baptista A, Bianchi L, et al. Histological gra-ding and staging of chronic hepatitis[J]. J Hepatol, 1995, 22(6):696-699. pmid: 7560864
[11]	Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2):281-297. doi: 10.1016/s0092-8674(04)00045-5 pmid: 14744438
[12]	Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes[J]. Oncogene, 2006, 25(46):6188-6196. pmid: 17028598
[13]	Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues[J]. Oncogene, 2006, 25(17):2537-2545. pmid: 16331254
[14]	Mao B, Wang G. MicroRNAs involved with hepatocellular carcinoma(Review)[J]. Oncol Rep, 2015, 34(6):2811-2820. doi: 10.3892/or.2015.4275 URL
[15]	Kuo WT, Yu SY, Li SC, et al. MicroRNA-324 in human cancer: miR-324-5p and miR-324-3p have distinct biological functions in human cancer[J]. Anticancer Res, 2016, 36(10):5189-5196. doi: 10.21873/anticanres.11089 URL
[16]	Bamodu OA, Yang CK, Cheng WH, et al. 4-acetyl-antroquinonol B suppresses SOD2-enhanced cancer stem cell-like phenotypes and chemoresistance of colorectal cancer cells by inducing hsa-mir-324 re-expression[J]. Cancers(Basel), 2018, 10(8):269.
[17]	Zheng Z, Li J, An J, et al. High miR-324-5p expression predicts unfavorable prognosis of gastric cancer and faci-litates tumor progression in tumor cells[J]. Diagn Pathol, 2021, 16(1):5. doi: 10.1186/s13000-020-01063-2 URL
[18]	Rong Z, Wang Z, Wang X, et al. Molecular interplay between linc01134 and YY1 dictates hepatocellular carcinoma progression[J]. J Exp Clin Cancer Res, 2020, 39(1):61. doi: 10.1186/s13046-020-01551-9 URL
[19]	Huang X, Sun L, Wen S, et al. RNA sequencing of plasma exosomes revealed novel functional long noncoding RNAs in hepatocellular carcinoma[J]. Cancer Sci, 2020, 111(9):3338-3349. doi: 10.1111/cas.14516 URL

项目	miR-324-5p 低表达	miR-324-5p 高表达	P值
病例(n)	187	188
年龄			0.178
≤60	82 (21.9)	96 (25.7)
>60 NA^a)	105 (28.1) 0	91 (24.3) 1
性别			0.683
女	57 (15.2)	62 (16.5)
男	130 (34.7)	126 (33.6)
T分期			0.937
T₁	95 (25.5)	89 (23.9)
T₂	46 (12.4)	49 (13.2)
T₃	39 (10.5)	41 (11)
T₄ NA^a)	6 (1.6) 1	7 (1.9) 2
N分期			0.357
N₀	123 (47.3)	133 (51.2)
N₁ NA^a)	3 (1.2) 61	1 (0.4) 54
M分期			1.000
M₀	130 (47.3)	141 (51.3)
M₁ NA^a)	2 (0.7) 55	2 (0.7) 45
病理分期			0.898
Ⅰ	88 (25.1)	86 (24.5)
Ⅱ	42 (12)	45 (12.8)
Ⅲ	40 (11.4)	45 (12.8)
Ⅳ NA^a)	3 (0.9) 14	2 (0.6) 10
甲胎蛋白(μg/L)			<0.001^b)
≤400	127 (44.9)	91 (32.2)
>400 NA^a)	17 (6.0) 43	48 (17.0) 49
Child-Pugh分级			0.258
A	115 (47.1)	107 (43.9)
B	8 (3.3)	13 (5.3)
C NA^a)	1 (0.4) 63	0 68
Ishak评分			0.830
0	43 (19.7)	33 (15.1)
1/2	16 (7.3)	14 (6.4)
3/4	14 (6.4)	16 (7.3)
5/6 NA^a)	45 (20.6) 69	37 (17.0) 88
血管侵犯			0.598
无	110 (4.4)	98 (30.6)
有 NA^a)	55 (17.2) 22	57 (17.8) 33

项目	单因素分析		多因素分析
项目	HR (95%CI)	P值	HR (95%CI)	P值
年龄	1.222 (0.860~1.738)	0.263
性别	1.252 (0.875~1.792)	0.219
T分期	2.617 (1.834~3.736)	<0.001^a)	1.696 (0.233~12.356)	0.602
N分期	2.051 (0.503~8.372)	0.317
病理分期	2.519 (1.731~3.665)	<0.001^a)	1.541 (0.213~11.142)	0.668
甲胎蛋白	1.090 (0.667~1.784)	0.730
Child-Pugh分级	1.672 (0.825~3.391)	0.154
Ishak评分	0.764 (0.461~1.267)	0.297
血管侵犯	1.337 (0.882~2.028)	0.172
miR-324-5p表达	1.428 (1.006~2.026)	0.046^a)	1.537 (1.058~2.233)	0.024^a)